Basic Information
Clone | Gemtuzumab Biosimilar |
---|
Molecular Weight | 150 kDa |
---|
Endotoxin | <0.05EU/mg (<0.00005EU/μg)
Determined by LAL gel clotting assay |
---|
Sterility | 0.2 μm filtration |
---|
Aggregation | <5% Determined by SECP |
---|
Purity | >95% Determined by SDS-PAGE |
---|
Product Information
Production | Purified from cell culture supernatant in an animal-free facility |
---|
Purification | Protein A or G purification |
---|
Storage | 2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing) |
---|
Target Background
Gemtuzumab is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody Label. The antibody is specifically directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML). By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and causes cell death.Gemtuzumab is directed against the CD33 antigen expressed by hematopoietic cells. Binding of the anti-CD33 antibody portion of Gemtuzumab with the CD33 antigen results in the formation of a complex that is internalized. Upon internalization, the calicheamicin derivative is released inside the lysosomes of the myeloid cell. The released calicheamicin derivative binds to DNA in the minor groove resulting in site-specific DNA double strand breaks via formation of a p-benzene diradical. Eventually, cell death is induced.
Immunogen Information
Isotype | Human IgG4 kappa |
---|
Immunogen | Human CD80 |
---|
RecommendedIsotype Control(s) | In Vivo Grade Recombinant Human IgG4-S228P Kappa Isotype Control Antibody |
---|
Recommended Dilution Buffer | 1×PBS pH 7.0 |
---|
* For research use only. Not for therapeutic or diagnostic purposes.